Olema Pharmaceuticals, Inc.
OLMA
$5.13
$0.244.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.47M | 4.40M | 4.42M | 4.46M | 5.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.77M | 37.62M | 33.53M | 34.34M | 33.22M |
| Operating Income | -36.77M | -37.62M | -33.53M | -34.34M | -33.22M |
| Income Before Tax | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
| EBIT | -36.77M | -37.62M | -33.53M | -34.34M | -33.22M |
| EBITDA | -36.65M | -37.53M | -33.44M | -34.25M | -33.13M |
| EPS Basic | -0.51 | -0.60 | -0.54 | -0.56 | -0.49 |
| Normalized Basic EPS | -0.32 | -0.38 | -0.34 | -0.35 | -0.34 |
| EPS Diluted | -0.51 | -0.60 | -0.54 | -0.56 | -0.49 |
| Normalized Diluted EPS | -0.32 | -0.38 | -0.34 | -0.35 | -0.34 |
| Average Basic Shares Outstanding | 65.79M | 57.26M | 56.28M | 55.57M | 54.78M |
| Average Diluted Shares Outstanding | 65.79M | 57.26M | 56.28M | 55.57M | 54.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |